Epidemiological studies have revealed that there are profound differences in APOE-ε4 prevalence among AD patients, depending on their geographical background, with higher prevalence in Northern/Central Europe and Australia and lower prevalence in Southern Europe and Asia [46]. The gene discussed is APOE; the disease is Alzheimer disease.